Drug Trial Radar · NCT01714661
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
Last checked: Nov 20, 2026Latest source record: May 3, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
753
Actual
Start
Oct 2012
Primary completion
Dec 2015
Study completion Dec 2015
Sponsor
- Lead sponsor
- FORUM Pharmaceuticals IncIndustry
- Sponsor type
- Industry
- Collaborators
- Syneos Health; NeuroCog Trials, Inc.
- First posted
- Oct 26, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine if EVP-6124 (an alpha-7 nAChR agonist) enhances the cognitive abilities of subjects with Schizophrenia who are also taking stable antipsychotic therapy.
Conditions
- Schizophrenia
- Impaired Cognition
Interventions
EVP-6124Drug
Arms 1, 2
PlaceboDrug
Arm 3
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline in the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) to Day 182Time frame: Baseline to Day 182 or Early Termination
- Change from Baseline in the Schizophrenia Cognition Rating Scale (SCoRs) to Day 182Time frame: Baseline to Day 182 or Early Terminiation
- Safety and Tolerability of EVP-6124 or Placebo in Subjects with SchizophreniaTime frame: Screening (Day -42 to Day -15) to Day 182 or Early Terminiation
Locations
94 sites in 13 countries. Site status is shown where the registry gives one.
Site not named
Tucson, Arizona
Site not named
Anaheim, California
Site not named
Bellflower, California
Site not named
Costa Mesa, California
Site not named
Culver City, California
Site not named
Downey, California
Site not named
Escondido, California
Site not named
Los Angeles, California
Site not named
Oceanside, California
Site not named
Orange, California
Site not named
San Diego, California
Site not named
Torrance, California
Site not named
Lauderhill, Florida
Site not named
Miami, Florida
Site not named
North Miami, Florida
Site not named
Orange City, Florida
Site not named
Atlanta, Georgia
Site not named
Chicago, Illinois
Site not named
Wichita, Kansas
Site not named
Shreveport, Louisiana
Site not named
Minneapolis, Minnesota
Site not named
Flowood, Mississippi
Site not named
Creve Coeur, Missouri
Site not named
O'Fallon, Missouri
Site not named
St Louis, Missouri
Site not named
Omaha, Nebraska
Site not named
Marlton, New Jersey
Site not named
Albuquerque, New Mexico
Site not named
Cedarhurst, New York
Site not named
New York, New York
Site not named
Charlotte, North Carolina
Site not named
Durham, North Carolina
Site not named
Cleveland, Ohio
Site not named
Oklahoma City, Oklahoma
Site not named
Conshohocken, Pennsylvania
Site not named
Norristown, Pennsylvania
Site not named
Philadelphia, Pennsylvania
Site not named
Dallas, Texas
Site not named
La Plata, Buenos Aires, Argentina
Site not named
Caba, Buenos Aires F.D., Argentina
Showing 40 of 94 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.